No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GSK240628C41000
- 0.40
- +0.34+566.67%
15min DelayClose Jun 28 15:49 ET
0.40High0.40Low
0.40Open0.06Pre Close1 Volume67 Open Interest41.00Strike Price40.00Turnover1388.42%IV7.53%PremiumJun 28, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type0.2301Delta0.0977Gamma96.25Leverage Ratio-38.6046Theta0.0000Rho22.14Eff Leverage0.0007Vega
Intraday
- 5D
- Daily
News
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
GSK Reaches Confidential Settlement in Illinois Zantac Litigation
Express News | GSK Issues Statement Regarding The Zantac (Ranitidine) Litigation; Has Reached A Confidential Settlement With Martin Gross; GSK Does Not Admit Any Liability In This Settlement
GSK: Case Is Related to Ranitidine Litigation
GSK Will Continue to Vigorously Defend Itself, Manage Litigation in Best Interests of Group, Shareholders
Statement: Zantac (Ranitidine) Litigation – Gross Case
Comments
The term 'GRANOLAS' was coined by Goldman Sachs in 2020 based on a loose acronym of the stocks' names. It includes GlaxoSmithKline, Roche, ASML, Nestlé, Novartis, Novo Nordisk, L'Oréal, LVMH, AstraZeneca, SAP and Sanofi.
1
🚨 1 AdCom & 3 PDUFA decisions this week:
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : 🤔
⇨ Elafibranor
‣ Primary biliary cholangitis
‣ PDUFA date: 6/10/24
$Regeneron Pharmaceuticals(REGN.US$ : 🤔
⇨ Kevzara (sarilumab)
‣ Polyarticular juvenile idiopathic arthritis
‣ PDUFA date: 6/10/24
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇨ Augtyro™ (Repotrectinib)
‣ PDUFA date: 6/15/24 (sNDA)
🗓️ Last week’s PDUFAs:
$GlaxoSmithKline(GSK.US$ : Approved 6/7 🎉
⇨ Arexvy
‣ Respiratory s...
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : 🤔
⇨ Elafibranor
‣ Primary biliary cholangitis
‣ PDUFA date: 6/10/24
$Regeneron Pharmaceuticals(REGN.US$ : 🤔
⇨ Kevzara (sarilumab)
‣ Polyarticular juvenile idiopathic arthritis
‣ PDUFA date: 6/10/24
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇨ Augtyro™ (Repotrectinib)
‣ PDUFA date: 6/15/24 (sNDA)
🗓️ Last week’s PDUFAs:
$GlaxoSmithKline(GSK.US$ : Approved 6/7 🎉
⇨ Arexvy
‣ Respiratory s...
8
1
» 15+ upcoming FDA decisions to watch: 👀 👇
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Eli Lilly and Co(LLY.US$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro™ (Repotrectinib)
$Geron(GERN.US$ : Imetelstat
$Merck & Co(MRK.US$ : V116
$Amgen(AMGN.US$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics(SRPT.US$ : ELEVIDYS
$Merck & Co(MRK.US$ : KEYTRUDA ...
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Eli Lilly and Co(LLY.US$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro™ (Repotrectinib)
$Geron(GERN.US$ : Imetelstat
$Merck & Co(MRK.US$ : V116
$Amgen(AMGN.US$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics(SRPT.US$ : ELEVIDYS
$Merck & Co(MRK.US$ : KEYTRUDA ...
15
$GlaxoSmithKline(GSK.US$ do you guys think the fda case will be approved tomorrow? the company has had positive clinical trials.
1
See remaining FDA PDUFAs in May 👀👇
$Bristol-Myers Squibb(BMY.US$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna(MRNA.US$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals(CPRX.US$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro...
$Bristol-Myers Squibb(BMY.US$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna(MRNA.US$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals(CPRX.US$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro...
8
1
Read more